Skip to content
Monday, 16 November 2026
Inspire.News

Unveiling truth, one story at a time

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
Image: Business Insider

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify" style="text-align:justify;">ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the...

Full story

Continue reading this story on Business Insider, the publisher that reported it.

Read the full story at Business Insider ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

Topics in this story

More from Business

See all